FDA's Bulk Advertising Citations Continue: CSL Behring And Talecris Get Letters For Their Alpha1 Proteinase Inhibitors
This article was originally published in The Pink Sheet Daily
Firms were making similar claims that their products can reduce "lung function decline."
You may also be interested in...
“Sponsored searches” need to contain risk information, agency tells 14 firms in letters covering 48 products.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.